Oral anticoagulation has been shown to provide great benefit in preventing and treating thromboembolic disorders. The challenges of oral anticoagulation management in the elderly involve balancing the risks of bleeding versus the benefits of a life-saving treatment. Due to the complex nature of warfarin, therapy must be individualized with frequent monitoring, re-education, and adjustments based on concurrent illness and drug therapy. This review focuses on the use of warfarin, including indications, dosing recommendations, drug and dietary interactions, and reversal of anticoagulation. Methods to determine bleeding risks in this population and barriers that interfere with the prescribing of warfarin are discussed. Strategies to improve patient outcome and reduce adverse events are provided to assist clinicians in their decision-making skills. The potential advantages of anticoagulation clinics are summarized with regards to coordinating the care and minimizing the risks of anticoagulant therapy. The role of new-generation anticoagulants is also discussed as to their place in therapy.
Get full access to this article
View all access options for this article.
References
1.
1. Choonara IA, Malia RG, Haynes BP, et al. The relationship between inhibition of vitamin K 1,2,3-epoxide reductase and reduction of clotting factor activity with warfarin . Br J Clin Pharmacol. 1988;25: 1-7 .
2.
2. Vigano S, Mannucci PM, Solinas S, Botasso B, Mariani G. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy . Br J Haematol. 1984;57: 213-220 .
3.
3. Hellemans J, Vorlat M, Verstraete M. Survival time of pro-thrombin and factors VII, IX, X after complete synthesis blocking doses of coumarin derivatives . Br J Haematol. 1963;9: 506-512 .
4.
4. Fergusson RJ, Eade OE, Logie AW. A flexible loading dose schedule for warfarin therapy . Scott Med J. 1987;32: 169-171 .
5.
5. Mungall Dr, Ludden TM, Marshall J. Population kinetics of racemic warfarin in adult inpatients . J Pharmacokinet Biopharm. 1985;12: 213-227 .
6.
6. Gurwitz JH, Avorn J, Ross-Degnan D. Ageing and the antico-agulant response to warfarin therapy . Ann Intern Med. 1992;116: 901-904 .
7.
7. Aithal GP, Day CP, Kesteven PJ. Association of polymorphisms in the cytochrome P450 2C9 with warfarin dose requirements and risk of bleeding complications . Lancet. 1999;353: 717-719 .
8.
8. Booth SL, Sadowski JA, Weihrauch JL, Ferlan G. Vitamin K (phylloquinone) content of foods: a provisional table . J Food Consump Anal. 1993;6: 109-120 .
9.
9. Pedersen FM, Hamberg O, Hess K, Ovesen L. The effect of dietary vitamin K on warfarin-induced anticoagulation . J Intern Med. 1991;229: 517-520 .
10.
10. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range . Chest. 2001;119: 8S-21S .
11.
11. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes . Ann Pharmacother. 1995;29: 619-624 .
12.
12. Hermans JJR, Thijssen HHW. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines differences in their pharmacokinetics . Br J Pharmacol. 1993;110: 482-490 .
13.
13. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive anticoagulation . JAMA. 1997;126: 133-136 .
14.
14. Ulbricht CE. Herbs and supplements in anticoagulation . Pharmacy Practice News. August 2003; 95-99 .
15.
15. Harrison L, Johnston M, Massicotte MP. Comparison of 5 mg and 10 mg loading doses in initiation of warfarin therapy . Ann Intern Med. 1997;126: 133-136 .
16.
16. Henderson MC, White RH. Anticoagulation in the elderly . Curr Opin Pulm Med. 2001;7: 365-370 .
18. Weibert RT, Dzung TL, Kayser SR, Rapaport SI. Correction of excessive anticoagulation with low-dose oral vitamin K . Ann Intern Med. 1997;125: 959-962 .
19.
19. Pengo V, Banzato A, Garelli E. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K) compared with warfarin discontinuation . Blood Coagul Fibrinolysis. 1993;4: 739-741 .
20.
20. Feinberg WM, Blackshear JL, Laupacis A. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications . Arch Intern Med. 1995;155: 469 .
21.
21. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation . Chest. 2001;119: 194S-206S .
22.
22. Jorgensen HS, Nakayama H, Reith J. Acute stroke with atrial fibrillation: the Copenhagen Stroke Study . Stroke. 1996;27: 1765-1769 .
23.
23. Lin HJ, Wolf PA, Kelly-Hayes M. Stroke severity in atrial fibrillation: the Framingham Study . Stroke. 1996:27: 1760-1764 .
24.
24. Yader A, Scheinman M. Atrial fibrillation in the elderly . Am J Geriatric Cardiol. 2003;12(1): 49-56 .
25.
25. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in non-valvular atrial fibrillation . Stroke. 1990;21: 47-51 .
26.
26. Gullov AL, Koefoed BG, Petersen P. Fixed minidose warfarin and aspirin alone and in combination vs. adjusted dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation Study . Arch Intern Med. 1998;158: 1513-1521 .
27.
27. Ezelowitz MD, Bridges SL, James KE. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators . N Engl J Med. 1992;327: 1406-1412 .
28.
28. Connolly SJ, Laupacis A, Gent M. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study . J Am Coll Cardiol. 1991;18: 349-355 .
29.
29. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation . N Engl J Med. 1990;323: 1505-1511 .
30.
30. Stroke Prevention in Atrial Fibrillation Study. Final results . Circulation. 1991;84: 527-539 .
31.
31. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke . Lancet. 1993;342: 1255-1262 .
32.
32. Hylek EM, Skates SJ, Sheehan MA. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation . N Engl J Med. 1996; 355(8): 540-546 .
33.
33. Golzari H, Cebul RD, Bahler RC. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy . Ann Intern Med. 1996;125: 311-323 .
34.
34. VanGelder IC, Crijns HJ, Tieleman RG. Chronic atrial fibrillation: success of serial cardioversion therapy and safety of oral anticoagulation . Arch Intern Med. 1996;156: 2585-2592 .
35.
35. Weigner MJ, Caulfield TA, Danias PG. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours . Ann Intern Med. 1997;126(8): 615-620 .
36.
36. Arnold AZ, Mick MJ, Mazurek RP. Role of prophylactic anti-coagulation for direct cardioversion in patients with atrial fibrillation or atrial flutter . J Am Coll Cardiol. 1992;19: 851-855 .
37.
37. Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation . Am J Cardiol. 1989;63: 745-746 .
38.
38. Klein A, Grimm R, Murray D. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation . N Engl J Med. 2001;344(9): 1411-1420 .
39.
39. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, et al. Prevention of venous thromboembolism . Chest. 2001; 119: 132S-175S .
40.
40. Franzeck UK, Schalch I, Jager KA. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study) . Circulation. 1996;93: 74-79 .
41.
41. Prandoni P, Lensing AWA, Cogo A. The long-term clinical course of acute deep vein thrombosis . Ann Intern Med. 1996; 125: 1-7 .
42.
42. Samana MM, Cohen AT, Darman JY. A comparison of enoxaparin with placebo for the prevention of VTE in acutely ill medical patients . N Engl J Med. 1999;341: 793-800 .
43.
43. Hirsch J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight hepa-rin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety . Chest. 2001;119: 64S-94S .
44.
44. Berman AR, Arnsten JH. Diagnosis and treatment of pulmonary embolism in the elderly . Clin Geriatr Med. 2003;19: 157-175 .
45.
45. Hyers TM, Agnelli G, Hull RD, Morris TA, Samana M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease . Chest. 2001;119: 176S-193S .
46.
46. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulation treatment . Chest. 2001;119: 108S-121S .
47.
47. Hylek E, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin . Ann Intern Med. 1994;120: 897-902 .
48.
48. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation . Arch Intern Med. 1996;156: 409-416 .
49.
49. Byeth RJ, Quinn LM, Landefeld S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin . Am J Med. 1998;105: 91-99 .
50.
50. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke . Stroke. 1998;29: 1827-1832 .
51.
51. Brigden ML, Kay C, Le A, Graydon C, McLeod B. Audit of the frequency and clinical response to excessive oral anticoagulation in an outpatient population . Am J Hematol. 1998;59: 22-27 .
52.
52. Chiquette E, Amato MG, Bussey HI. Comparison of an anti-coagulation clinic with usual medical care: anticoagulant control, patient outcomes and healthcare costs . Arch Intern Med. 1998;158: 1641-1647 .
53.
53. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement . N Engl J Med. 2003;349(18): 703-712 .
54.
54. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prophylaxis of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran . N Engl J Med. 2003; 349(18): 1713-1721 .
55.
55. Wallentin L, Wilcox RL, Weaver WD. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial . Lancet. 2003;362: 789-797 .
56.
56. Eriksson UG, Bredberg U, Gisler K. Pharmacokinetic and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor in young healthy male subjects . Eur J Clin Pharmacol. 2003;59: 35-43 .
